Biofrontera

Biofrontera Equity Turnover

The Equity Turnover of Biofrontera (B8FK.DE) as of Nov 15, 2026 is 0.88. In the previous year, Equity Turnover was 0.65 — a change of 36.95% (higher).

Equity Turnover

0.88

YoY

36.95%

Last updated:

Equity Turnover of Biofrontera is 2025 0.88 . Equity Turnover of Biofrontera was 2024 0.65 . It decreases by 36.95% higher compared to the previous year.

The Biofrontera Equity Turnover history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Turnover
Date
Equity Turnover
Jan 1, 2018
1.29 EUR
Jan 1, 2019
3.14 EUR
Jan 1, 2020
4.11 EUR
Jan 1, 2021
0.50 EUR
Jan 1, 2022
1.27 EUR
Jan 1, 2023
1.61 EUR
Jan 1, 2024
0.65 EUR
Jan 1, 2025
0.88 EUR
The Biofrontera Equity Turnover history
YEAREquity TurnoverYoY
0.88+36.95%
0.65-59.97%
1.61+27.53%
1.27+152.48%
0.50-87.82%
4.11+31.02%
3.14+143.37%
1.29-63.72%
3.56+819.12%
0.39-144.97%
-0.86-99.42%
-147.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biofrontera Stock analysis

What does Biofrontera do? Biofrontera AG generates revenue by developing, selling, and distributing dermatological drugs and medical cosmetics for skin care, protection, and treatment. The company markets its portfolio which includes Ameluz for the photodynamic therapy of actinic keratoses, the PDT lamp BF-RhodoLED used in conjunction with Ameluz treatment, and Belixos, a herbal dermatological cream for conditions such as insect bites, burns, neurodermatitis, and psoriasis. These products address the needs of patients and healthcare providers seeking treatments for skin diseases and regenerative care of damaged skin. The firm also engages in the clinical development of drug candidates to expand its future revenue streams. This includes BF-derm1, a tablet containing an inhibitor that blocks histamine synthesis to prevent allergic reactions, and BF1, a selective serotonin receptor agent aimed at preventing migraines. Through its five wholly owned subsidiaries, notably B, Biofrontera AG supports these development and distribution activities from its headquarters in Leverkusen, Nordrhein-Westfalen. Biofrontera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biofrontera stock

Equity Turnover of Biofrontera is 0.88 in 2025.

Equity Turnover of Biofrontera changed from 0.65 to 0.88, representing a 36.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Equity Turnover Biofrontera since 2006 – with annual values, charts, and detailed analysis.

Equity turnover measures how efficiently a company uses shareholders' equity to generate revenue. It is a component of the DuPont analysis framework.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Turnover's Biofrontera with sector peers and the industry average to assess whether it is attractive.

To evaluate Equity Turnover's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Equity Turnover.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Biofrontera

All Key Metrics — Biofrontera